QuidelOrtho (QDEL) Expected to Post Quarterly Earnings on Tuesday

QuidelOrtho (NASDAQ:QDEL) is projected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.2023 per share and revenue of $627.83 million for the quarter. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL) last released its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The company had revenue of $630.90 million during the quarter, compared to analyst estimates of $618.72 million. During the same period in the prior year, the firm posted $0.12 EPS. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. On average, analysts expect QuidelOrtho to post $0.75 EPS for the current fiscal year and $1.45 EPS for the next fiscal year.

QuidelOrtho Price Performance

NASDAQ QDEL opened at $13.68 on Tuesday. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. QuidelOrtho has a 12 month low of $9.92 and a 12 month high of $35.58. The stock has a market cap of $938.24 million, a price-to-earnings ratio of -0.89 and a beta of 0.79. The company’s 50 day moving average is $12.80 and its two-hundred day moving average is $16.87.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on QDEL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, October 15th. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a report on Monday, June 29th. JPMorgan Chase & Co. boosted their price objective on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Wednesday, July 1st. Citigroup upped their price objective on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Finally, Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $13.62.

QuidelOrtho Company Profile

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.